Gold prices remain near record highs; Fed cut bets prompt weekly gains
WAYNE, Pa. - Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company with a market capitalization of $225 million and strong recent performance showing a 76% return over the past year, announced Tuesday that additional data from its Phase 2a trial of ATI-2138 for moderate-to-severe atopic dermatitis will be presented at the upcoming European Academy of Dermatology and Venereology Congress in Paris.
The late-breaking abstract was selected for oral presentation on September 18, according to a company press release. Dr. Jessica Beaziz-Tordjman, a French dermatologist and senior associate researcher at the Icahn School of Medicine at Mount Sinai, will deliver the presentation titled "Molecular and Clinical Effects of oral ATI-2138, an ITK/JAK3 inhibitor, in Moderate-to-Severe Atopic Dermatitis." According to InvestingPro data, three analysts have recently revised their earnings estimates upward for the upcoming period, suggesting growing confidence in the company’s pipeline.
ATI-2138 is described as a selective oral covalent inhibitor that targets both interleukin-2-inducible T cell kinase (ITK) and Janus kinase 3 (JAK3). These enzymes play key roles in T cell function and inflammatory pathways.
The clinical-stage biopharmaceutical company focuses on developing treatments for immuno-inflammatory diseases. Aclaris noted that preclinical studies and early clinical trial data support further investigation of ATI-2138 for conditions dependent on T cell function and IL-2 receptor common gamma chain signaling.
The EADV Congress, scheduled for September 17-20, 2025, serves as a major forum for dermatology research presentations. The company did not disclose specific efficacy or safety data in its announcement, indicating these details will be revealed during the conference presentation.
In other recent news, Aclaris Therapeutics announced positive top-line results from its Phase 2a trial of ATI-2138, an oral inhibitor targeting specific kinases, in patients with moderate-to-severe atopic dermatitis. The trial met its primary safety endpoint, showing a favorable tolerability profile without severe adverse events. This clinical success involved 14 patients receiving 10mg of ATI-2138 twice daily over 12 weeks. Additionally, Aclaris Therapeutics has been added to the Russell 3000 and Russell 2000 indexes following the 2025 Russell US Indexes annual reconstitution. This inclusion is effective at the opening of U.S. equity markets and will last for one year. Furthermore, H.C. Wainwright maintained its Buy rating for Aclaris, with a price target of $16.00, citing strong drug performance in trials. The firm highlighted that 94% of participants in the Phase 2a trial achieved significant improvements in their skin condition. These developments have led Aclaris to initiate a more rigorous Phase 2 trial to further evaluate the drug’s efficacy and safety.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.